Warning letter
Infupharma, LLC: warning letter of Jul 30, 2012
FDA warning letter UCM317190 · Florida District Office
Key facts
| Reference number | UCM317190 |
|---|---|
| Company | Infupharma, LLC |
| Subject | CGMP for Finished Pharmaceutical/Adulterated |
| Issue date | Jul 30, 2012 |
| Posted date | Jul 30, 2012 |
| Issuing office | Florida District Office |
| Product type | Drugs |
| CFR sections cited | 211.167(a), 210, 211.188, 211.25(a), 211.42(c)(10), 211.68(a), 211.113(b), 211.166(a), 211.198(a) |
| Country | 3 |
| Inspection city | Hollywood |
| Inspection ZIP | 33020 |
| Inspection start date | Jul 18, 2011 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: